Glucose-coated Berberine Nanodrug for Glioma Therapy through Mitochondrial Pathway

Shubin Wang,1,* Juan An,2,* Weiwei Dong,3,* Xin Wang,4 Jianqiu Sheng,4 Yan Jia,4 Yuqi He,4 Xianzong Ma,4 Jiheng Wang,4 Dedong Yu,1 Xiuqin Jia,1 Bingyu Wang,5 Wenbo Yu,5 Kejia Liu,5 Yuanyuan Zhao,6 Yun Wu,1 Wei Zhu,1 Yuanming Pan1,4,6 1Department of Oncology, Baotou City Central Hospital, Baotou 0140...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wang S, An J, Dong W, Wang X, Sheng J, Jia Y, He Y, Ma X, Wang J, Yu D, Jia X, Wang B, Yu W, Liu K, Zhao Y, Wu Y, Zhu W, Pan Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	berberine glioma glucose-nanocarrier nanoparticles mitochondria Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/709b9334b1374c6294fe501ca15658ac
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:709b9334b1374c6294fe501ca15658ac
record_format	dspace
institution	DOAJ
collection	DOAJ
language	EN
topic	berberine glioma glucose-nanocarrier nanoparticles mitochondria Medicine (General) R5-920
spellingShingle	berberine glioma glucose-nanocarrier nanoparticles mitochondria Medicine (General) R5-920 Wang S An J Dong W Wang X Sheng J Jia Y He Y Ma X Wang J Yu D Jia X Wang B Yu W Liu K Zhao Y Wu Y Zhu W Pan Y Glucose-coated Berberine Nanodrug for Glioma Therapy through Mitochondrial Pathway
description	Shubin Wang,1,* Juan An,2,* Weiwei Dong,3,* Xin Wang,4 Jianqiu Sheng,4 Yan Jia,4 Yuqi He,4 Xianzong Ma,4 Jiheng Wang,4 Dedong Yu,1 Xiuqin Jia,1 Bingyu Wang,5 Wenbo Yu,5 Kejia Liu,5 Yuanyuan Zhao,6 Yun Wu,1 Wei Zhu,1 Yuanming Pan1,4,6 1Department of Oncology, Baotou City Central Hospital, Baotou 014040, People’s Republic of China; 2Department of Basic Research Medical Sciences, Qinghai University, Xining 810001, People’s Republic of China; 3Department of Oncology, General Hospital of Chinese People’s Liberation Army, Beijing 100085, People’s Republic of China; 4Department of Gastroenterology, The 7th Medical Center of Chinese PLA General Hospital, Beijing 100700, People’s Republic of China; 5Yidu Cloud (Beijing) Technology Co. Ltd 8F, Health Work, Beijing 100083, People’s Republic of China; 6National Center for Nanoscience and Technology, Zhongguancun, Beijing 100190, People’s Republic of ChinaThese authors contributed equally to this workCorrespondence: Yuanming PanNational Center for Nanoscience and Technology, Zhongguancun, Beijing 100190, People’s Republic of ChinaTel +86-10-6406-9831Fax +86-10-6401-2266Email panym@nanoctr.cnWei ZhuDepartment of Oncology, Baotou City Central Hospital, Baotou, Inner Mongolia 01404, People’s Republic of ChinaTel +86-472-6955473Fax +86-472-6955708Email 18686111667@163.comIntroduction: Glioma is the primary malignant brain tumor with poor prognosis. Berberine (BBR) was the potential drug for anti-tumor in glioma cells. Based on its limitation of poor aqueous solubility and instability, little information of BBR nanoparticles is reported in glioma.Methods: Different solutions including 5% glucose, 1PBS, ddH2O, 0.9% NaCl, cell culture medium were selected, and only 5% glucose and ddH2O exhibited BBR-related nanoparticles. After heating for a longer time or adding a higher concentration of glucose solution, BBR nanoparticles were detected by TEM analysis. The uptake of BBR-Glu or BBR-Water nanoparticles were detected by immunofluorescence analysis for BBR autofluorescence. Cell viability was measured by MTT assay and Western blotting analysis. Apoptosis was performed with flow cytometric analysis and was detected by cleaved caspase-3 immuno-fluorescent staining. Cell cycle was used by flow cytometric analysis. Cytoskeleton was observed by confocal analysis using the neuron specific Class III ß-tubulin and ß-tubulin antibodies. Mitochondrial-related proteins were detected by Western blotting analyses and mito-tracker staining in live cells. Mitochondrion structures were observed by TEM analysis. ROS generation and ATP production were detected by related commercial kits. The tracking of BBR-Glu or BBR-Water nanoparticles into blood–brain barrier was observed in primary tumor-bearing models. The fluorescence of BBR was detected by confocal analyses in brains and gliomas.Results: BBR-Glu nanoparticles became more homogenized and smaller with dose- and time-dependent manners. BBR-Glu nanoparticles were easily absorbed in glioma cells. The IC50 of BBR-Glu in U87 and U251 was far lower than that of BBR-Water. BBR-Glu performed better cytotoxicity, with higher G2/M phase arrest, decreased cell viability by targeting mitochondrion. In primary U87 glioma-bearing mice, BBR-Glu exhibited better imaging in brains and gliomas, indicating that more BBR moved across the blood–brain tumor barrier.Discussion: BBR-Glu nanoparticles have better solubility and stability, providing a promising strategy in glioma precision treatment.Keywords: berberine, glioma, glucose-nanocarrier, nanoparticles, mitochondria
format	article
author	Wang S An J Dong W Wang X Sheng J Jia Y He Y Ma X Wang J Yu D Jia X Wang B Yu W Liu K Zhao Y Wu Y Zhu W Pan Y
author_facet	Wang S An J Dong W Wang X Sheng J Jia Y He Y Ma X Wang J Yu D Jia X Wang B Yu W Liu K Zhao Y Wu Y Zhu W Pan Y
author_sort	Wang S
title	Glucose-coated Berberine Nanodrug for Glioma Therapy through Mitochondrial Pathway
title_short	Glucose-coated Berberine Nanodrug for Glioma Therapy through Mitochondrial Pathway
title_full	Glucose-coated Berberine Nanodrug for Glioma Therapy through Mitochondrial Pathway
title_fullStr	Glucose-coated Berberine Nanodrug for Glioma Therapy through Mitochondrial Pathway
title_full_unstemmed	Glucose-coated Berberine Nanodrug for Glioma Therapy through Mitochondrial Pathway
title_sort	glucose-coated berberine nanodrug for glioma therapy through mitochondrial pathway
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/709b9334b1374c6294fe501ca15658ac
work_keys_str_mv	AT wangs glucosecoatedberberinenanodrugforgliomatherapythroughmitochondrialpathway AT anj glucosecoatedberberinenanodrugforgliomatherapythroughmitochondrialpathway AT dongw glucosecoatedberberinenanodrugforgliomatherapythroughmitochondrialpathway AT wangx glucosecoatedberberinenanodrugforgliomatherapythroughmitochondrialpathway AT shengj glucosecoatedberberinenanodrugforgliomatherapythroughmitochondrialpathway AT jiay glucosecoatedberberinenanodrugforgliomatherapythroughmitochondrialpathway AT hey glucosecoatedberberinenanodrugforgliomatherapythroughmitochondrialpathway AT max glucosecoatedberberinenanodrugforgliomatherapythroughmitochondrialpathway AT wangj glucosecoatedberberinenanodrugforgliomatherapythroughmitochondrialpathway AT yud glucosecoatedberberinenanodrugforgliomatherapythroughmitochondrialpathway AT jiax glucosecoatedberberinenanodrugforgliomatherapythroughmitochondrialpathway AT wangb glucosecoatedberberinenanodrugforgliomatherapythroughmitochondrialpathway AT yuw glucosecoatedberberinenanodrugforgliomatherapythroughmitochondrialpathway AT liuk glucosecoatedberberinenanodrugforgliomatherapythroughmitochondrialpathway AT zhaoy glucosecoatedberberinenanodrugforgliomatherapythroughmitochondrialpathway AT wuy glucosecoatedberberinenanodrugforgliomatherapythroughmitochondrialpathway AT zhuw glucosecoatedberberinenanodrugforgliomatherapythroughmitochondrialpathway AT pany glucosecoatedberberinenanodrugforgliomatherapythroughmitochondrialpathway
_version_	1718397694897029120
spelling	oai:doaj.org-article:709b9334b1374c6294fe501ca15658ac2021-12-02T10:04:38ZGlucose-coated Berberine Nanodrug for Glioma Therapy through Mitochondrial Pathway1178-2013https://doaj.org/article/709b9334b1374c6294fe501ca15658ac2020-10-01T00:00:00Zhttps://www.dovepress.com/glucose-coated-berberine-nanodrug-for-glioma-therapy-through-mitochond-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Shubin Wang,1,* Juan An,2,* Weiwei Dong,3,* Xin Wang,4 Jianqiu Sheng,4 Yan Jia,4 Yuqi He,4 Xianzong Ma,4 Jiheng Wang,4 Dedong Yu,1 Xiuqin Jia,1 Bingyu Wang,5 Wenbo Yu,5 Kejia Liu,5 Yuanyuan Zhao,6 Yun Wu,1 Wei Zhu,1 Yuanming Pan1,4,6 1Department of Oncology, Baotou City Central Hospital, Baotou 014040, People’s Republic of China; 2Department of Basic Research Medical Sciences, Qinghai University, Xining 810001, People’s Republic of China; 3Department of Oncology, General Hospital of Chinese People’s Liberation Army, Beijing 100085, People’s Republic of China; 4Department of Gastroenterology, The 7th Medical Center of Chinese PLA General Hospital, Beijing 100700, People’s Republic of China; 5Yidu Cloud (Beijing) Technology Co. Ltd 8F, Health Work, Beijing 100083, People’s Republic of China; 6National Center for Nanoscience and Technology, Zhongguancun, Beijing 100190, People’s Republic of ChinaThese authors contributed equally to this workCorrespondence: Yuanming PanNational Center for Nanoscience and Technology, Zhongguancun, Beijing 100190, People’s Republic of ChinaTel +86-10-6406-9831Fax +86-10-6401-2266Email panym@nanoctr.cnWei ZhuDepartment of Oncology, Baotou City Central Hospital, Baotou, Inner Mongolia 01404, People’s Republic of ChinaTel +86-472-6955473Fax +86-472-6955708Email 18686111667@163.comIntroduction: Glioma is the primary malignant brain tumor with poor prognosis. Berberine (BBR) was the potential drug for anti-tumor in glioma cells. Based on its limitation of poor aqueous solubility and instability, little information of BBR nanoparticles is reported in glioma.Methods: Different solutions including 5% glucose, 1PBS, ddH2O, 0.9% NaCl, cell culture medium were selected, and only 5% glucose and ddH2O exhibited BBR-related nanoparticles. After heating for a longer time or adding a higher concentration of glucose solution, BBR nanoparticles were detected by TEM analysis. The uptake of BBR-Glu or BBR-Water nanoparticles were detected by immunofluorescence analysis for BBR autofluorescence. Cell viability was measured by MTT assay and Western blotting analysis. Apoptosis was performed with flow cytometric analysis and was detected by cleaved caspase-3 immuno-fluorescent staining. Cell cycle was used by flow cytometric analysis. Cytoskeleton was observed by confocal analysis using the neuron specific Class III ß-tubulin and ß-tubulin antibodies. Mitochondrial-related proteins were detected by Western blotting analyses and mito-tracker staining in live cells. Mitochondrion structures were observed by TEM analysis. ROS generation and ATP production were detected by related commercial kits. The tracking of BBR-Glu or BBR-Water nanoparticles into blood–brain barrier was observed in primary tumor-bearing models. The fluorescence of BBR was detected by confocal analyses in brains and gliomas.Results: BBR-Glu nanoparticles became more homogenized and smaller with dose- and time-dependent manners. BBR-Glu nanoparticles were easily absorbed in glioma cells. The IC50 of BBR-Glu in U87 and U251 was far lower than that of BBR-Water. BBR-Glu performed better cytotoxicity, with higher G2/M phase arrest, decreased cell viability by targeting mitochondrion. In primary U87 glioma-bearing mice, BBR-Glu exhibited better imaging in brains and gliomas, indicating that more BBR moved across the blood–brain tumor barrier.Discussion: BBR-Glu nanoparticles have better solubility and stability, providing a promising strategy in glioma precision treatment.Keywords: berberine, glioma, glucose-nanocarrier, nanoparticles, mitochondriaWang SAn JDong WWang XSheng JJia YHe YMa XWang JYu DJia XWang BYu WLiu KZhao YWu YZhu WPan YDove Medical Pressarticleberberinegliomaglucose-nanocarriernanoparticlesmitochondriaMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 15, Pp 7951-7965 (2020)

Glucose-coated Berberine Nanodrug for Glioma Therapy through Mitochondrial Pathway

Ejemplares similares